Literature DB >> 33741892

Venetoclax combination therapy induces deep AML remission with eradication of leukemic stem cells and remodeling of clonal haematopoiesis.

Romain Vazquez1, Claire Breal2, Didier Bouscary2,3, Nicolas Chapuis4,5, Loria Zalmai1, Chloe Friedrich1,3, Carole Almire1, Adrien Contejean2, Sylvain Barreau1,3, Eric Grignano2,3, Lise Willems2,3, Benedicte Deau-Fischer2, Patricia Franchi2, Marguerite Vignon2, Justine Decroocq2, Rudy Birsen2, Lauriane Goldwirt6, Sophie Kaltenbach7,8, Lucile Couronne7,9, Michaela Fontenay1,3, Olivier Kosmider1,3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33741892      PMCID: PMC7979724          DOI: 10.1038/s41408-021-00448-w

Source DB:  PubMed          Journal:  Blood Cancer J        ISSN: 2044-5385            Impact factor:   11.037


× No keyword cloud information.
  15 in total

1.  High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study.

Authors:  François Vergez; Alexa S Green; Jerome Tamburini; Jean-Emmanuel Sarry; Baptiste Gaillard; Pascale Cornillet-Lefebvre; Melanie Pannetier; Aymeric Neyret; Nicolas Chapuis; Norbert Ifrah; François Dreyfus; Stéphane Manenti; Cecile Demur; Eric Delabesse; Catherine Lacombe; Patrick Mayeux; Didier Bouscary; Christian Recher; Valerie Bardet
Journal:  Haematologica       Date:  2011-09-20       Impact factor: 9.941

2.  Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells.

Authors:  Xiaojia Niu; Jianyun Zhao; Jun Ma; Chengzhi Xie; Holly Edwards; Guan Wang; J Timothy Caldwell; Shengyan Xiang; Xiaohong Zhang; Roland Chu; Zhihong J Wang; Hai Lin; Jeffrey W Taub; Yubin Ge
Journal:  Clin Cancer Res       Date:  2016-04-21       Impact factor: 12.531

3.  The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells.

Authors:  Tamilla Nechiporuk; Stephen E Kurtz; Olga Nikolova; Tingting Liu; Courtney L Jones; Angelo D'Alessandro; Rachel Culp-Hill; Amanda d'Almeida; Sunil K Joshi; Mara Rosenberg; Cristina E Tognon; Alexey V Danilov; Brian J Druker; Bill H Chang; Shannon K McWeeney; Jeffrey W Tyner
Journal:  Cancer Discov       Date:  2019-05-02       Impact factor: 39.397

Review 4.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Authors:  Hartmut Döhner; Elihu Estey; David Grimwade; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Hervé Dombret; Benjamin L Ebert; Pierre Fenaux; Richard A Larson; Ross L Levine; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel Sanz; Jorge Sierra; Martin S Tallman; Hwei-Fang Tien; Andrew H Wei; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2016-11-28       Impact factor: 22.113

5.  Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells.

Authors:  Courtney L Jones; Brett M Stevens; Angelo D'Alessandro; Julie A Reisz; Rachel Culp-Hill; Travis Nemkov; Shanshan Pei; Nabilah Khan; Biniam Adane; Haobin Ye; Anna Krug; Dominik Reinhold; Clayton Smith; James DeGregori; Daniel A Pollyea; Craig T Jordan
Journal:  Cancer Cell       Date:  2018-11-12       Impact factor: 31.743

6.  Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia.

Authors:  Daniel A Pollyea; Brett M Stevens; Courtney L Jones; Amanda Winters; Shanshan Pei; Mohammad Minhajuddin; Angelo D'Alessandro; Rachel Culp-Hill; Kent A Riemondy; Austin E Gillen; Jay R Hesselberth; Diana Abbott; Derek Schatz; Jonathan A Gutman; Enkhtsetseg Purev; Clayton Smith; Craig T Jordan
Journal:  Nat Med       Date:  2018-11-12       Impact factor: 53.440

7.  Molecular Minimal Residual Disease in Acute Myeloid Leukemia.

Authors:  Mojca Jongen-Lavrencic; Tim Grob; Diana Hanekamp; François G Kavelaars; Adil Al Hinai; Annelieke Zeilemaker; Claudia A J Erpelinck-Verschueren; Patrycja L Gradowska; Rosa Meijer; Jacqueline Cloos; Bart J Biemond; Carlos Graux; Marinus van Marwijk Kooy; Markus G Manz; Thomas Pabst; Jakob R Passweg; Violaine Havelange; Gert J Ossenkoppele; Mathijs A Sanders; Gerrit J Schuurhuis; Bob Löwenberg; Peter J M Valk
Journal:  N Engl J Med       Date:  2018-03-29       Impact factor: 91.245

8.  Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.

Authors:  Courtney D DiNardo; Keith Pratz; Vinod Pullarkat; Brian A Jonas; Martha Arellano; Pamela S Becker; Olga Frankfurt; Marina Konopleva; Andrew H Wei; Hagop M Kantarjian; Tu Xu; Wan-Jen Hong; Brenda Chyla; Jalaja Potluri; Daniel A Pollyea; Anthony Letai
Journal:  Blood       Date:  2018-10-25       Impact factor: 22.113

9.  High frequency of CD34+CD38-/low immature leukemia cells is correlated with unfavorable prognosis in acute myeloid leukemia.

Authors:  Adriana Plesa; Charles Dumontet; Eve Mattei; Ines Tagoug; Sandrine Hayette; Pierre Sujobert; Isabelle Tigaud; Marie Pierre Pages; Youcef Chelghoum; Fiorenza Baracco; Helene Labussierre; Sophie Ducastelle; Etienne Paubelle; Franck Emmanuel Nicolini; Mohamed Elhamri; Lydia Campos; Claudiu Plesa; Stéphane Morisset; Gilles Salles; Yves Bertrand; Mauricette Michallet; Xavier Thomas
Journal:  World J Stem Cells       Date:  2017-12-26       Impact factor: 5.326

10.  Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia.

Authors:  Shanshan Pei; Daniel A Pollyea; Annika Gustafson; Brett M Stevens; Mohammad Minhajuddin; Rui Fu; Kent A Riemondy; Austin E Gillen; Ryan M Sheridan; Jihye Kim; James C Costello; Maria L Amaya; Anagha Inguva; Amanda Winters; Haobin Ye; Anna Krug; Courtney L Jones; Biniam Adane; Nabilah Khan; Jessica Ponder; Jeffrey Schowinsky; Diana Abbott; Andrew Hammes; Jason R Myers; John M Ashton; Travis Nemkov; Angelo D'Alessandro; Jonathan A Gutman; Haley E Ramsey; Michael R Savona; Clayton A Smith; Craig T Jordan
Journal:  Cancer Discov       Date:  2020-01-23       Impact factor: 39.397

View more
  4 in total

1.  The impact of venetoclax based regimens in the preemptive of measurable residual disease in acute myeloid leukemia.

Authors:  Qiuyun Fang; Xiaoyuan Gong; Yan Li; Benfa Gong; Yuntao Liu; Kaiqi Liu; Guangji Zhang; Shuning Wei; Dong Lin; Bingcheng Liu; Ying Wang; Hui Wei; Yingchang Mi; Jianxiang Wang
Journal:  Blood Sci       Date:  2022-01-25

Review 2.  MRD in Venetoclax-Based Treatment for AML: Does it Really Matter?

Authors:  Massimo Bernardi; Felicetto Ferrara; Matteo Giovanni Carrabba; Sara Mastaglio; Francesca Lorentino; Luca Vago; Fabio Ciceri
Journal:  Front Oncol       Date:  2022-07-18       Impact factor: 5.738

Review 3.  Properties of Leukemic Stem Cells in Regulating Drug Resistance in Acute and Chronic Myeloid Leukemias.

Authors:  Xingjian Zhai; Xiaoyan Jiang
Journal:  Biomedicines       Date:  2022-07-30

4.  Targeting EZH2 Promotes Chemosensitivity of BCL-2 Inhibitor through Suppressing PI3K and c-KIT Signaling in Acute Myeloid Leukemia.

Authors:  Chan Yang; Yan Gu; Zheng Ge; Chunhua Song
Journal:  Int J Mol Sci       Date:  2022-09-27       Impact factor: 6.208

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.